Cost-effectiveness of terlipressin for hepatorenal syndrome: The United States hospital perspective.

HRS patients treated with terlipressin experienced better clinical outcomes and a lower cost per treatment response vs alternative treatments. ICU days and pharmacy costs were key cost drivers distinguishing the treatment groups. These outcomes suggest that terlipressin is cost-effective on the basis of total cost per response achieved.